Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026
MWN-AI** Summary
Revvity, Inc. (NYSE: RVTY) made a significant impact at SLAS2026 in Boston (February 7-11) by unveiling several high-impact discovery platforms aimed at expediting drug discovery workflows. Among the innovations presented are the Opera Phenix OptIQ™ high-content screening system, EnVision Nexus™ One multimode plate reader, and the AssayMate™ workstation, all designed to enhance laboratory efficiency from sample to insight.
The Opera Phenix OptIQ system offers advanced solutions for phenotypic screening and cellular analysis, boasting a dramatic increase in camera quantum efficiency from 60% to 95%, which significantly improves sensitivity and data quality. Its integration with Phenologic.AI enhances image analysis capabilities to include new features like cell cycle analysis, moving beyond basic segmentation.
Complementing this, the EnVision Nexus One multimode plate reader streamlines processes in high-throughput screening environments with its single-detector configuration. This system enhances sensitivity for various detection techniques and comes equipped with Kaleido™ software that ensures compliance with industry standards.
The AssayMate workstation introduces automation for labs of all sizes, supporting liquid handling volumes between 3–1000 µL without the need for head changes. Its intelligent features include pressure-based liquid level detection and workflow error handling, promoting reliability and efficiency.
Kevin Quick, Revvity's VP of platforms, stated that these launches reflect the company’s commitment to meet the evolving needs of discovery labs. With a focus on integrating automation, trusted assay technologies, and AI-driven imaging, Revvity aims to accelerate results while maintaining high data quality. Revvity serves a broad customer base, including pharmaceutical, biotech, and academic sectors, further establishing itself as a leader in health science solutions.
MWN-AI** Analysis
Revvity, Inc. (NYSE: RVTY) has made significant strides in the biotech and pharmaceutical sectors through its recent product launches showcased at SLAS2026. The introduction of the Opera Phenix OptIQ™ high-content screening system, EnVision Nexus™ One multimode plate reader, and AssayMate™ workstation reflects Revvity’s commitment to enhancing drug discovery workflows.
Investors should view these developments as potential catalysts for growth. The Opera Phenix OptIQ™ system's advances in image sensitivity and AI-driven analysis could drastically reduce bottlenecks in drug discovery, appealing to a wide array of laboratories that prioritize efficiency. High-throughput environments will likely find the EnVision Nexus One advantageous, as it offers enhanced integration and sensitivity, helping clients to adapt to evolving assay needs. The AssayMate workstation further signifies Revvity's strategy to democratize technology in laboratories of any size, a crucial move as automation becomes increasingly vital in clinical settings.
Given Revvity's position in the S&P 500 and its substantial 2025 revenue of $2.9 billion, the financial robustness adds a layer of stability for investors. Revvity's solutions span crucial areas such as imaging, screening, and diagnostics, which positions the company as a leader in a fast-growing market.
However, potential investors should remain cautious. Market dynamics and competitive pressures in biotech can influence Revvity’s performance. Keeping an eye on how these innovations are adopted and their impact on translating research into viable products is essential. Given the increasing significance of technological integration in drug discovery, these new platforms could very well enhance Revvity’s market position, making it a stock worth considering for those interested in the biotech field.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
New launches in high-content imaging, detection, and automation help labs accelerate drug discovery workflows from sample to insight
Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are the Opera Phenix OptIQ™ high-content screening system , the EnVision Nexus™ One multimode plate reader , and the AssayMate™ workstation , alongside other recently introduced solutions spanning sample preparation, screening, advanced imaging, and lab automation.
At booth #612, Revvity will showcase an expanded portfolio of integrated workflow solutions designed to support discovery programs from early screening through data-driven decision making. Solutions debuting at SLAS2026 include:
- Opera Phenix OptIQ high-content screening system : Designed to reduce bottlenecks in phenotypic screening and advanced cellular analysis, this system enables quantitative imaging across complex biological models, including 3D organoids and organ-on-chip systems. Peak camera quantum efficiency has increased from 60% to 95%, improving image sensitivity and data quality, and the system is equipped with Phenologic.AI image analysis software that now includes new classification capabilities, such as cell cycle analysis, expanding beyond its previous focus on segmentation. Laser-based autofocus has been enhanced to better support multi-layer sample carriers, and a new Harmony™ software building block enables detection of organoids in brightfield image stacks.
- EnVision Nexus One multimode plate reader : The newest addition to the EnVision Nexus family, the EnVision Nexus One delivers the trusted sensitivity and reliability of the Envision Nexus platform in a streamlined single-detector configuration optimized for high-throughput screening environments. Designed to simplify automation and integration while supporting evolving assay needs, the system provides enhanced sensitivity across TRF, Alpha, and luminescence detection. The EnVision Nexus One is powered by intuitive Kaleido™ software with 21 CFR Part 11 compliance tools and offers flexible configuration options to support a wide range of laboratory workflows.
- AssayMate workstation : The compact, benchtop AssayMate liquid handler delivers intelligent automation performance for labs of any size. It supports a wide volume range of 3–1000 µL without requiring head changes, using a fixed 8-channel head and gripper configuration. Intelligent features such as pressure-based liquid level detection (PLLD) and built-in workflow error handling—including detection of missing plate lids—enable reliable operation and quick experiment resumption. A reconfigurable recessed deck accommodates optional modules such as heater shakers, heater coolers, and magnetic blocks, while AssayPREP™ software provides a user-friendly, drag-and-drop interface that requires minimal training.
“SLAS2026 marks a key milestone for Revvity with the introduction of new platforms that support the evolving needs of discovery labs,” said Kevin Quick, vice president, platforms, Revvity. “These launches integrate automation, trusted assay technologies, and AI-driven imaging to help customers accelerate results while maintaining data quality.”
For more information on Revvity’s new product launches, demonstrations, and conference activities at SLAS2026, visit booth #612 or this link .
For research use only. Not for use in diagnostic procedures.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Stay updated by following our Newsroom , LinkedIn , X , YouTube , Facebook and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260205915069/en/
Investor Relations
Steve Willoughby
steve.willoughby@revvity.com
Media Relations
Chet Murray
(781) 462-5126
chet.murray@revvity.com
FAQ**
How do Revvity Inc. RVTY's new product launches at SLAS2026 enhance their competitive position in the high-content imaging market for drug discovery?
What specific improvements in image sensitivity and data quality can customers expect from the new Opera Phenix OptIQ system launched by Revvity Inc. RVTY at SLAS2026?
How does the AssayMate workstation from Revvity Inc. RVTY integrate automation capabilities to optimize workflows in laboratories of varying sizes?
In what ways does the EnVision Nexus One multimode plate reader from Revvity Inc. RVTY adapt to evolving assay needs while maintaining compliance for high-throughput screening environments?
**MWN-AI FAQ is based on asking OpenAI questions about Revvity Inc. (NYSE: RVTY).
NASDAQ: RVTY
RVTY Trading
-4.26% G/L:
$88.93 Last:
100,115 Volume:
$90 Open:
